A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN Filo in Malian Adults Aged 18-50 Years

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 3390107A (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
Indications Ebola virus infections
Focus Adverse reactions

Most Recent Events

27 Oct 2017 Status changed from active, no longer recruiting to completed.
17 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
11 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight